Convergence Financial LLC lowered its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 52.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,250 shares of the medical research company’s stock after selling 2,448 shares during the period. Convergence Financial LLC’s holdings in Thermo Fisher Scientific were worth $1,519,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in Thermo Fisher Scientific in the 2nd quarter valued at $15,501,867,000. Corient Private Wealth LP bought a new position in Thermo Fisher Scientific during the 2nd quarter worth $382,547,000. Bank of New York Mellon Corp acquired a new stake in shares of Thermo Fisher Scientific during the second quarter worth $1,974,561,000. Bank of America Corp DE acquired a new stake in shares of Thermo Fisher Scientific during the second quarter worth $1,952,930,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Thermo Fisher Scientific by 0.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,472,524 shares of the medical research company’s stock valued at $1,239,625,000 after acquiring an additional 22,827 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several equities analysts recently commented on the stock. Morgan Stanley upped their price target on shares of Thermo Fisher Scientific from $650.00 to $730.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. Citigroup raised their price target on shares of Thermo Fisher Scientific from $685.00 to $800.00 and gave the stock a “buy” rating in a research report on Friday, October 23rd. DZ Bank cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 23rd. Evercore set a $570.00 price objective on shares of Thermo Fisher Scientific in a report on Monday, July 6th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $720.00 target price on shares of Thermo Fisher Scientific in a research report on Friday, September 25th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $684.55.
Insider Activity
In other news, CEO Marc Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $629.27, for a total value of $6,292,700.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $77,982,284.75. The trade was a 7.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph Holmes sold 420 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the sale, the chief accounting officer directly owned 2,966 shares of the company’s stock, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 73,368 shares of company stock valued at $43,896,820 over the last quarter. 0.33% of the stock is owned by corporate insiders.
Thermo Fisher Scientific Stock Up 1.6%
TMO stock opened at $704.41 on Thursday. The company has a market cap of $260.45 billion, a PE ratio of 37.15, a price-to-earnings-growth ratio of 2.75 and a beta of 0.87. The business has a 50-day simple moving average of $651.61 and a 200 day simple moving average of $552.09. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $710.84. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.71.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its quarterly earnings data on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, topping the consensus estimate of $6.40 by $0.28. The business had revenue of $12.14 billion during the quarter, compared to analysts’ expectations of $11.95 billion. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. Thermo Fisher Scientific’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.79 earnings per share. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 25.23 EPS for the current fiscal year.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.
Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.
Featured Articles
- Five stocks we like better than Thermo Fisher Scientific
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
